| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $160.8M | — | -26.2% |
| Cost of Revenue | $125.9M | — | -26.6% |
| R&D Expense | $11.4M | — | -36.0% |
| SG&A Expense | $32.5M | — | +2.6% |
| Operating Income | -$9.0M | — | -178.4% |
| Pre-tax Income | -$13.4M | — | -137.3% |
| Income Tax | $1.4M | — | -9.6% |
| Net Income | -$27.9M | — | -288.0% |
| EPS (Basic) | -$1.00 | — | -284.6% |
| EPS (Diluted) | -$1.00 | — | -284.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $70.5M | +6.5% | -10.8% |
| Accounts Receivable | $140.2M | +6.6% | -10.6% |
| Inventory | $111.3M | -16.1% | -26.7% |
| Current Assets | $348.0M | -3.8% | -16.8% |
| Total Assets | $512.0M | -7.1% | -22.1% |
| Current Liabilities | $172.6M |
| -1.5% |
| Stockholders' Equity | $156.2M | -13.1% | -38.3% |